The CEO of Arcturus on data presented today for an inhaled mRNA therapy at the 47th European Cystic Fibrosis Conference

blonca9
Jun 7, 2024
1 min read

Joseph Payne describes data from the first four patients with CF to receive this inhaled mRNA at #ECFS2024. He also summarizes Arcturus' approach to mRNA and LNPs, and the company's broader pipeline.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

The CEO of Arcturus on data presented today for an inhaled mRNA therapy at the 47th European Cystic Fibrosis Conference

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight